GluK2 kainate receptor subunit-selective, potentiating RNA aptamer.

Samantha R Ingenito, Noah Saunders, Kyle J Lininger, Li Niu

Abstract read

In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Samantha R IngenitoDepartment of Chemistry, Center for Neuroscience Research and RNA Institute, University at Albany, State University of New York, Albany, NY, 12222, USA.

Noah SaundersDepartment of Chemistry, Center for Neuroscience Research and RNA Institute, University at Albany, State University of New York, Albany, NY, 12222, USA.

Kyle J LiningerDepartment of Chemistry, Center for Neuroscience Research and RNA Institute, University at Albany, State University of New York, Albany, NY, 12222, USA.

Li NiuDepartment of Chemistry, Center for Neuroscience Research and RNA Institute, University at Albany, State University of New York, Albany, NY, 12222, USA. lniu@albany.edu.

Funding

Animal testing of RNA aptamers as ALS drug candidateR01NS121793 · NINDS · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI NIU, LI · 2022 to 2025

$1.5M

NIH HHS 1RO1NS121793NINDS NIH HHS R01 NS121793

6 · The paper itself

Abstract

Kainate receptors are a subtype of ionotropic glutamate receptors. Potent and selective modulatory agents of kainate receptors are potential drug candidates for treatment of various neurological diseases involving receptor dysregulation. Here, we report an RNA aptamer that selectively potentiates GluK2, a key kainate receptor subunit. The potentiating aptamer, termed U9, is designed by changing the sequence of the predecessor RNA, which is an inhibitor without subunit selectivity, leading to the change of function: U9 selectively potentiates GluK2 with an EC

Indexed as

Aptamers, NucleotideKainic Acid ReceptorsAnimalsGluK2 Kainate ReceptorHEK293 CellsHumansMolecular Docking SimulationProtein SubunitsAptamers, NucleotideGluK2 Kainate ReceptorKainic Acid ReceptorsProtein Subunits

Identifiers

PMID40935837

DOI10.1038/s41598-025-15323-y

PMCPMC12426214

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.